Early off-label treatment during pandemics? A dilemma

Jan A. Roth; Tala Ballouz; Roger D. Kouyos; Manuel Battegay

doi:10.4414/smw.2020.20281

Viewpoint

Vol. 150 No. 1920 (2020)

Early off-label treatment during pandemics? A dilemma

Jan A. Roth
Tala Ballouz
Roger D. Kouyos
Manuel Battegay

DOI: https://doi.org/10.4414/smw.2020.20281
Cite this as:: Swiss Med Wkly. 2020;150:w20281
Published: 11.05.2020

References

Baden LR, Rubin EJ. Covid-19 - the search for effective therapy. N Engl J Med. 2020;382(19):1851–2. doi:.https://doi.org/10.1056/NEJMe2005477
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–99; Epub ahead of print. doi:.https://doi.org/10.1056/NEJMoa2001282
Rome BN, Avorn J. Drug evaluation during the Covid-19 pandemic. N Engl J Med. 2020;NEJMp2009457. doi:.https://doi.org/10.1056/NEJMp2009457
Simon GE, Platt R, Hernandez AF. Evidence from pragmatic trials during routine care - slouching toward a learning health system. N Engl J Med. 2020;382(16):1488–91. doi:.https://doi.org/10.1056/NEJMp1915448
Ladanie A, Ioannidis JPA, Stafford RS, Ewald H, Bucher HC, Hemkens LG. Off-label treatments were not consistently better or worse than approved drug treatments in randomized trials. J Clin Epidemiol. 2018;94:35–45. doi:.https://doi.org/10.1016/j.jclinepi.2017.11.006

Publication image

How to Cite

1.

Roth JA, Ballouz T, Kouyos RD, Battegay M. Early off-label treatment during pandemics? A dilemma. Swiss Med Wkly [Internet]. 2020 May 11 [cited 2024 Nov. 17];150(1920):w20281. Available from: https://smw.ch/index.php/smw/article/view/2787

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Most read articles by the same author(s)

Marcel Salathé, Christian L. Althaus, Richard Neher, Silvia Stringhini, Emma Hodcroft, Jacques Fellay, Marcel Zwahlen, Gabriela Senti, Manuel Battegay, Annelies Wilder-Smith, Isabella Eckerle, Matthias Egger, Nicola Low, COVID-19 epidemic in Switzerland: on the importance of testing, contact tracing and isolation , Swiss Medical Weekly: Vol. 150 No. 1112 (2020)
Marcel Salathé, Christian L. Althaus, Nanina Anderegg, Daniele Antonioli, Tala Ballouz, Edouard Bugnion, Srdjan Čapkun, Dennis Jackson, Sang-Il Kim, James R. Larus, Nicola Low, Wouter Lueks, Dominik Menges, Cédric Moullet, Mathias Payer, Julien Riou, Theresa Stadler, Carmela Troncoso, Effy Vayena, Viktor von Wyl, Early evidence of effectiveness of digital contact tracing for SARS-CoV-2 in Switzerland , Swiss Medical Weekly: Vol. 150 No. 5153 (2020)
Jérémie Scire, Sarah Nadeau, Timothy G. Vaughan, Gavin Brupbacher, Simon Fuchs, Jürg Sommer, Katrin N. Koch, Reto Misteli, Lukas Mundorff, Thomas Götz, Tobias Eichenberger, Carlos Quinto, Miodrag Savic, Andrea Meienberg, Thilo Burkard, Michael Mayr, Christoph A. Meier, Andreas Widmer, Richard Kuehl, Adrian Egli, Hans H. Hirsch, Stefano Bassetti, Christian H. Nickel, Katharina M. Rentsch, Werner Kübler, Roland Bingisser, Manuel Battegay, Sarah Tschudin-Sutter, Tanja Stadler, Reproductive number of the COVID-19 epidemic in Switzerland with a focus on the Cantons of Basel-Stadt and Basel-Landschaft , Swiss Medical Weekly: Vol. 150 No. 1920 (2020)
Manuel Battegay, Richard Kuehl, Sarah Tschudin-Sutter, Hans H. Hirsch, Andreas F. Widmer, Richard A. Neher, 2019-Novel Coronavirus (2019-nCoV): estimating the case fatality rate – a word of caution , Swiss Medical Weekly: Vol. 150 No. 0506 (2020)
Maroussia Roelens, Alexis Martin, Brian Friker, Filipe Maximiano Sousa, Amaury Thiabaud, Beatriz Vidondo, Valentin Buchter, Céline Gardiol, Jasmin Vonlanthen, Carlo Balmelli, Manuel Battegay, Christoph Berger, Michael Buettcher, Alexia Cusini, Domenica Flury, Ulrich Heininger, Anita Niederer-Loher, Thomas Riedel, Peter W. Schreiber, Rami Sommerstein, Nicolas Troillet, Sarah Tschudin-Sutter, Pauline Vetter, Sara Bernhard-Stirnemann, Natascia Corti, Roman Gaudenz, Jonas Marschall, Yvonne Nussbaumer-Ochsner, Laurence Senn, Danielle Vuichard-Gysin, Petra Zimmermann, Franziska Zucol, Anne Iten, Olivia Keiser, Evolution of COVID-19 mortality over time: results from the Swiss hospital surveillance system (CH-SUR) , Swiss Medical Weekly: Vol. 151 No. 4748 (2021)
Mihaela Sava, Gregor Sommer, Thomas Daikeler, Anne-Kathrin Woischnig, Aurélien E. Martinez, Karoline Leuzinger, Hans H. Hirsch, Tobias E. Erlanger, Andrea Wiencierz, Stefano Bassetti, Michael Tamm, Sarah Tschudin-Sutter, Marcel Stoeckle, Hans Pargger, Martin Siegemund, Renate Boss, Gert Zimmer, Diem-Lan Vu, Laurent Kaiser, Salome Dell-Kuster, Maja Weisser, Manuel Battegay, Katrin E. Hostettler, Nina Khanna, Ninety-day outcome of patients with severe COVID-19 treated with tocilizumab – a single centre cohort study , Swiss Medical Weekly: Vol. 151 No. 3132 (2021)
Babette L. Winter, Frédérique Hovaguimian, Roger D. Kouyos, Axel Jeremias Schmidt, Enos Bernasconi, Dominique L. Braun, Alexandra Calmy, Julia Notter, Marcel Stoeckle, Bernard Surial, Vanessa Christinet, Matthias Cavassini, Carsten Depmeier, Severin Läuchli, Emmanuelle Boffi El Amari, Matthias Reinacher, Manuela Rasi, Philip Bruggmann, David Haerry, Raphaël Bize, Nicola Low, Andreas Lehner, Boris B. Quednow, Jan S. Fehr, Benjamin Hampel, Changes in mental and sexual health among MSM using HIV pre-exposure prophylaxis during the SARS-CoV-2 pandemic: longitudinal analysis of the SwissPrEPared cohort study , Swiss Medical Weekly: Vol. 152 No. 2526 (2022)
Matthias Diebold, Aurélien E. Martinez, Kai-Manuel Adam, Stefano Bassetti, Michael Osthoff, Elianne Kassi, Jürg Steiger, Hans Pargger, Martin Siegemund, Manuel Battegay, Nina Khanna, Stefan Schaub, Conrad Wesch, Michael Dickenmann, Maja Weisser, Temporal trends of COVID-19 related in-hospital mortality and demographics in Switzerland – a retrospective single centre cohort study , Swiss Medical Weekly: Vol. 151 No. 2930 (2021)
Jan A. Sidler, Manuel Battegay, Sarah Tschudin-Sutter, Andreas F. Widmer, Maja Weisser, Enterococci, Clostridium difficile and ESBL-producing bacteria: epidemiology, clinical impact and prevention in ICU patients , Swiss Medical Weekly: Vol. 144 No. 3940 (2014)
Paola Daniore, Tala Ballouz, Dominik Menges, Viktor von Wyl, The SwissCovid Digital Proximity Tracing App after one year: Were expectations fulfilled? , Swiss Medical Weekly: Vol. 151 No. 3536 (2021)

1 2 3 > >>

[1] Baden LR, Rubin EJ. Covid-19 - the search for effective therapy. N Engl J Med. 2020;382(19):1851–2. doi:.https://doi.org/10.1056/NEJMe2005477

[2] Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–99; Epub ahead of print. doi:.https://doi.org/10.1056/NEJMoa2001282

[3] Rome BN, Avorn J. Drug evaluation during the Covid-19 pandemic. N Engl J Med. 2020;NEJMp2009457. doi:.https://doi.org/10.1056/NEJMp2009457

[4] Simon GE, Platt R, Hernandez AF. Evidence from pragmatic trials during routine care - slouching toward a learning health system. N Engl J Med. 2020;382(16):1488–91. doi:.https://doi.org/10.1056/NEJMp1915448

[5] Ladanie A, Ioannidis JPA, Stafford RS, Ewald H, Bucher HC, Hemkens LG. Off-label treatments were not consistently better or worse than approved drug treatments in randomized trials. J Clin Epidemiol. 2018;94:35–45. doi:.https://doi.org/10.1016/j.jclinepi.2017.11.006